Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences515 enrolled

Overview

The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of sacituzumab govitecan-hziy administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

The outcome measures are planned to be assessed up to the data cutoff date. Following the data cutoff date, the participants will either stay on the study and will be followed for safety data collection or rolled into another Gilead-sponsored study. Therefore, only safety data will be collected after the data cutoff date.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

515

Conditions

Gastric Adenocarcinoma Esophageal Cancer

Interventions

Sacituzumab Govitecan-hziy (SG)DRUG

Administered via intravenous (IV) infusion

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals able to understand and give written informed consent. * Histologically or cytologically confirmed epithelial cancer of one of the following types: * Gastric adenocarcinoma (GC) * Esophageal cancer (EC) * Hepatocellular carcinoma (HCC) * Non-small-cell lung cancer (NSCLC) * Small-cell lung cancer (SCLC) * Epithelial ovarian cancer (EOC) * Cervical Cancer * Endometrial Cancer * Triple-negative breast cancer (TNBC) * Non-triple-negative breast cancer * Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and anaplastic thyroid cancer) * Glioblastoma multiforme (GBM) * Hormone-refractory prostate cancer (HRPC) * Head and neck cancers- squamous cell (SCCHN) * Renal cell cancer (clear cell) (RCC) * Urothelial cancer * Stage IV (metastatic) disease (except for individuals with GBM). * Refractory to or relapsed after at least one prior standard therapeutic regimen * Adequate performance status (ECOG 0 or 1) * Expected survival ≥ 6 months. * Measurable disease by CT or MRI. * At least 2 weeks beyond treatment (chemotherapy, investigational drugs including small molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities to Grade 1 or less (except alopecia). * At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids \< 20 mg prednisone or equivalent daily are permitted). * Adequate hematology without ongoing transfusional support (hemoglobin \> 9 g/dL, absolute neutrophil count (ANC) \> 1,500 per mm\^3, platelets \> 100,000 per mm\^3). * Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases). * Otherwise, all toxicity at study entry ≤ Grade 1. Exclusion Criteria: * Women who are pregnant or lactating. * Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period. * Individuals with Gilbert's disease. * Individuals with brain metastases can be enrolled only if treated, non-progressive brain metastases and off high-dose steroids (\> 20 mg prednisone or equivalent) for at least 4 weeks. * Presence of bulky disease (defined as any single mass \> 7 cm in its greatest dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be considered for enrollment after discussion and approval with the medical monitor. * Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction. * Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval. * Individuals known to be HIV positive, hepatitis B positive, or hepatitis C positive. * Known history of unstable angina, MI, or CHF present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy. * Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months. * Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment. * Infection requiring intravenous antibiotic use within 1 week. * History of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior irinotecan, * Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Locations (12)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Yale University School of Medicine

New Haven, Connecticut, United States

Helen F. Graham Cancer Center

Newark, Delaware, United States

MD Anderson Cancer Center Orlando (UF Health Cancer Center)

Orlando, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

IU Health Goshen Cancer Center

Goshen, Indiana, United States

Massachusettes General Hospital

Boston, Massachusetts, United States

Weill Cornell/New York Presbyterian Hospital

New York, New York, United States

Columbia University Herbert Irving Cancer Center

New York, New York, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

...and 2 more locations

Outcomes

Primary Outcomes

Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) were defined as any adverse events (AEs) that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population.

Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months) plus 30 days

Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death

Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).

Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)

Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events

Time frame: First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)

Objective Response Rate (ORR) by Independent Central Review (ICR)

ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by ICR assessment according to RECIST1.1. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \<10 mm. PR was defined as ≥ 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.